EPP 16th Life Sciences Pricing Forum 2026
CONTENT HUB
Access exclusive, industry-led insights for free! Complete the form once to unlock all current and future content – no repeated sign-ups needed
The MFN Reckoning
How US Most Favoured Nation Pricing Is Reshaping European Life Sciences Strategy
Based on 35+ confidential interviews with senior pricing, market access, and commercial leaders across pharma, biotech, and MedTech, this white paper explores how the industry is responding to the growing impact of the US Most Favoured Nation (MFN) pricing policy.
Discover key insights on launch sequencing, international reference pricing, net price confidentiality, innovative contracting, and the future of global market access.
Broader value framework beyond traditional individual health and healthcare system value
What does “value” really mean in Life Sciences today?
In this keynote, Jiri Smejkal – Global Head of Pricing& Tender Excellence – Takeda explores how value is evolving beyond traditional HTA frameworks toward a more holistic, multi-stakeholder perspective.
The session looks at how factors such as treatment setting (home vs hospital), patient impact, and system-wide outcomes are reshaping how value is defined, assessed, and communicated.
▶ Watch the keynote to discover how pricing leaders can better reflect real-world value in their strategies.
Q2 2025 Drug Contracting Trends Report:
The Great GLP-1 Rush
Lyfegen’s latest report offers fresh insights into how payers and pharma are tackling access and affordability challenges—especially amid rising demand for GLP-1 therapies and obesity treatments.
Built on 8,000+ real-world agreements from 25 countries, the report highlights how outcome guarantees, budget caps, and conditional reimbursement models are shaping drug pricing strategies for high-cost therapies like gene therapies and GLP-1s.
Key takeaways include:
- Emerging models to manage clinical and financial risk
- Real-world contracting trends and regional shifts across Europe, North America, and Asia
- Strategic recommendations for pharma, including value segmentation, long-term outcomes planning, and reframing obesity as a chronic condition
The report offers a global view of the evolving market access landscape—and how smarter strategies are unlocking better drug access in 2025 and beyond.
Pricing Insights – How to Use Data to Inform Pricing Strategy
In this keynote, Ulrik Haagen Panton, VP Global Pricing at Novo Nordisk, explores how data-driven insights can shape smarter pricing strategies. Gain a clear understanding of the value of pricing analytics, its role in execution, and the key challenges and opportunities in applying it across pharma, biotech, and MedTech.